BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease

Saideh Fakharzadeh,1,2 Hassan Argani,1 Simin Dadashzadeh,3 Somayeh Kalanaky,2 Peyman Mohammadi Torbati,4 Mohammad Hassan Nazaran,2 Abbas Basiri5 1Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Research and Development, Sodour Ahra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fakharzadeh S, Argani H, Dadashzadeh S, Kalanaky S, Mohammadi Torbati P, Nazaran MH, Basiri A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	bcc1 diabetic kidney disease chronic kidney disease nanochelating technology iron Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/6ca95d4cb0cc4c39978d2b738cb55c0c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ca95d4cb0cc4c39978d2b738cb55c0c
record_format	dspace
spelling	oai:doaj.org-article:6ca95d4cb0cc4c39978d2b738cb55c0c2021-12-02T09:24:29ZBCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease1178-7007https://doaj.org/article/6ca95d4cb0cc4c39978d2b738cb55c0c2020-04-01T00:00:00Zhttps://www.dovepress.com/bcc1-nanomedicine-therapeutic-effects-in-streptozotocin-and-high-fat-d-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Saideh Fakharzadeh,1,2 Hassan Argani,1 Simin Dadashzadeh,3 Somayeh Kalanaky,2 Peyman Mohammadi Torbati,4 Mohammad Hassan Nazaran,2 Abbas Basiri5 1Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 3Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Department of Pathology, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 5Urology and Nephrology Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranCorrespondence: Mohammad Hassan NazaranDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, IranTel/ Fax +98 21 88992123Email mnazaran@nanochelatingtechnology.comAbbas BasiriUrology and Nephrology Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranTel/ Fax +98 21 22567222Email basiri@unrc.irBackground: One common feature of chronic diseases, such as cancer, diabetes and chronic kidney disease (CKD), is the disruption of iron metabolism and increase in labile iron pool, which can result in excessive production of harmful oxidative stress. The proper management of iron metabolism in this situation can be a valuable tool to ameliorate pathological events.Materials and Methods: In the previous studies, the anti-neoplastic effects of BCc1, a nanochelating-based nanomedicine with iron-chelating property, were demonstrated in cell culture, animal models and clinical trials. In the present study, the therapeutic effects of BCc1 in animal model of diabetic kidney disease (DKD), induced by streptozotocin injection (35 mg/kg) and high-fat diet consumption, were evaluated.Results: The results showed that BCc1 significantly decreased HOMA-IR index, uric acid, blood urea nitrogen, malondialdehyde and 8-isoprostane. In addition, it reduced urinary albumin excretion rate and albumin-to-creatinine ratio in comparison to DKD control rats. This nanomedicine had no negative impact on liver iron content, hemoglobin level, red blood cell count, hematocrit and mean corpuscular volume, while it significantly decreased aspartate aminotransferase and alanine aminotransferase compared to DKD control group. Moreover, the histopathological assessment indicated that lesser glomerular basement membrane and wrinkling, mesangial matrix expansion and pathological changes in proximal cortical tubules were seen in the kidney samples of BCc1-treated rats.Conclusion: In conclusion, BCc1 as an iron-chelating agent shows promising impacts in DKD animal model, which can ameliorate biochemical and pathological events of this disease.Keywords: BCc1, diabetic kidney disease, chronic kidney disease, nanochelating technology, ironFakharzadeh SArgani HDadashzadeh SKalanaky SMohammadi Torbati PNazaran MHBasiri ADove Medical Pressarticlebcc1diabetic kidney diseasechronic kidney diseasenanochelating technologyironSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 13, Pp 1179-1188 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	bcc1 diabetic kidney disease chronic kidney disease nanochelating technology iron Specialties of internal medicine RC581-951
spellingShingle	bcc1 diabetic kidney disease chronic kidney disease nanochelating technology iron Specialties of internal medicine RC581-951 Fakharzadeh S Argani H Dadashzadeh S Kalanaky S Mohammadi Torbati P Nazaran MH Basiri A BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease
description	Saideh Fakharzadeh,1,2 Hassan Argani,1 Simin Dadashzadeh,3 Somayeh Kalanaky,2 Peyman Mohammadi Torbati,4 Mohammad Hassan Nazaran,2 Abbas Basiri5 1Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 2Department of Research and Development, Sodour Ahrar Shargh Company, Tehran, Iran; 3Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 4Department of Pathology, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran; 5Urology and Nephrology Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranCorrespondence: Mohammad Hassan NazaranDepartment of Research and Development, Sodour Ahrar Shargh Company, Tehran, IranTel/ Fax +98 21 88992123Email mnazaran@nanochelatingtechnology.comAbbas BasiriUrology and Nephrology Research Center, Shahid Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IranTel/ Fax +98 21 22567222Email basiri@unrc.irBackground: One common feature of chronic diseases, such as cancer, diabetes and chronic kidney disease (CKD), is the disruption of iron metabolism and increase in labile iron pool, which can result in excessive production of harmful oxidative stress. The proper management of iron metabolism in this situation can be a valuable tool to ameliorate pathological events.Materials and Methods: In the previous studies, the anti-neoplastic effects of BCc1, a nanochelating-based nanomedicine with iron-chelating property, were demonstrated in cell culture, animal models and clinical trials. In the present study, the therapeutic effects of BCc1 in animal model of diabetic kidney disease (DKD), induced by streptozotocin injection (35 mg/kg) and high-fat diet consumption, were evaluated.Results: The results showed that BCc1 significantly decreased HOMA-IR index, uric acid, blood urea nitrogen, malondialdehyde and 8-isoprostane. In addition, it reduced urinary albumin excretion rate and albumin-to-creatinine ratio in comparison to DKD control rats. This nanomedicine had no negative impact on liver iron content, hemoglobin level, red blood cell count, hematocrit and mean corpuscular volume, while it significantly decreased aspartate aminotransferase and alanine aminotransferase compared to DKD control group. Moreover, the histopathological assessment indicated that lesser glomerular basement membrane and wrinkling, mesangial matrix expansion and pathological changes in proximal cortical tubules were seen in the kidney samples of BCc1-treated rats.Conclusion: In conclusion, BCc1 as an iron-chelating agent shows promising impacts in DKD animal model, which can ameliorate biochemical and pathological events of this disease.Keywords: BCc1, diabetic kidney disease, chronic kidney disease, nanochelating technology, iron
format	article
author	Fakharzadeh S Argani H Dadashzadeh S Kalanaky S Mohammadi Torbati P Nazaran MH Basiri A
author_facet	Fakharzadeh S Argani H Dadashzadeh S Kalanaky S Mohammadi Torbati P Nazaran MH Basiri A
author_sort	Fakharzadeh S
title	BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease
title_short	BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease
title_full	BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease
title_fullStr	BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease
title_full_unstemmed	BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease
title_sort	bcc1 nanomedicine therapeutic effects in streptozotocin and high-fat diet induced diabetic kidney disease
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/6ca95d4cb0cc4c39978d2b738cb55c0c
work_keys_str_mv	AT fakharzadehs bcc1nanomedicinetherapeuticeffectsinstreptozotocinandhighfatdietinduceddiabetickidneydisease AT arganih bcc1nanomedicinetherapeuticeffectsinstreptozotocinandhighfatdietinduceddiabetickidneydisease AT dadashzadehs bcc1nanomedicinetherapeuticeffectsinstreptozotocinandhighfatdietinduceddiabetickidneydisease AT kalanakys bcc1nanomedicinetherapeuticeffectsinstreptozotocinandhighfatdietinduceddiabetickidneydisease AT mohammaditorbatip bcc1nanomedicinetherapeuticeffectsinstreptozotocinandhighfatdietinduceddiabetickidneydisease AT nazaranmh bcc1nanomedicinetherapeuticeffectsinstreptozotocinandhighfatdietinduceddiabetickidneydisease AT basiria bcc1nanomedicinetherapeuticeffectsinstreptozotocinandhighfatdietinduceddiabetickidneydisease
_version_	1718398126339915776

BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease

Ejemplares similares